Meeting NewsVideo

VIDEO: Echosens discusses future of Fibroscan with new biomarkers

SAN FRANCISCO — In this exclusive video from The Liver Meeting 2018, Sven Henrichwark, CEO of Echosens, discusses the company’s Fibroscan technology and the potential to combine Fibroscan with new biomarkers and scoring systems.

“Initially, in the identification space, just about everybody uses us as an identification technology and also an exploratory endpoint for clinical trials, but then later on in the all-important monitoring space,” Henrichwark told Healio Gastroenterology and Liver Disease. “It gives an indication of how much value there will be in developing more complicated, more complex scores, combining Fibroscan and other biomarkers depending on what the clinicians are looking for.”

According to Henrichwark, AASLD selected 143 abstracts and 11 oral presentations submitted by Echosens for this year’s meeting, the highlight of which he felt were data on liver stiffness and steatosis scores.

“This is all very exciting, very promising, not just for the field of [nonalcoholic steatohepatitis] but for patients in general,” Henrichwark said. “Something that takes 2 or 3 minutes to do delivers a great value already and can be combined with other things to develop more value in the future in terms of scores and algorithms.”

Disclosure: Henrichwark is the CEO of Echosens.

SAN FRANCISCO — In this exclusive video from The Liver Meeting 2018, Sven Henrichwark, CEO of Echosens, discusses the company’s Fibroscan technology and the potential to combine Fibroscan with new biomarkers and scoring systems.

“Initially, in the identification space, just about everybody uses us as an identification technology and also an exploratory endpoint for clinical trials, but then later on in the all-important monitoring space,” Henrichwark told Healio Gastroenterology and Liver Disease. “It gives an indication of how much value there will be in developing more complicated, more complex scores, combining Fibroscan and other biomarkers depending on what the clinicians are looking for.”

According to Henrichwark, AASLD selected 143 abstracts and 11 oral presentations submitted by Echosens for this year’s meeting, the highlight of which he felt were data on liver stiffness and steatosis scores.

“This is all very exciting, very promising, not just for the field of [nonalcoholic steatohepatitis] but for patients in general,” Henrichwark said. “Something that takes 2 or 3 minutes to do delivers a great value already and can be combined with other things to develop more value in the future in terms of scores and algorithms.”

Disclosure: Henrichwark is the CEO of Echosens.

    See more from The Liver Meeting